Featured Research

from universities, journals, and other organizations

Adolescent amphetamine use linked to permanent changes in brain function and behavior

Date:
November 3, 2011
Source:
McGill University Health Centre
Summary:
Amphetamine use in adolescence can cause neurobiological imbalances and increase risk-taking behavior, and these effects can persist into adulthood, even when subjects are drug free. These are the conclusions of a new study using animal models. The study is one of the first to shed light on how long-term amphetamine use in adolescence affects brain chemistry and behavior.

Amphetamine use in adolescence can cause neurobiological imbalances and increase risk-taking behaviour, and these effects can persist into adulthood, even when subjects are drug free. These are the conclusions of a new study using animal models conducted by McGill University Health Centre (MUHC) researcher Dr. Gabriella Gobbi and her colleagues. The study, published in The International Journal of Neuropsychopharmacology, is one of the first to shed light on how long-term amphetamine use in adolescence affects brain chemistry and behaviour.

"We looked at the effects of long-term amphetamine use on important neurotransmitters and on risk-taking behaviour in adolescent rats," says Dr. Gobbi, a researcher in Mental Illness and Addiction from the Research Institute of the MUHC and associate professor at the Faculty of Medicine at McGill University. "The brain chemistry of these rodents is very similar to that of humans, so this model provided us with very useful insights into amphetamine use in a human population."

Amphetamine is a psychostimulant drug which produces increased wakefulness and focus, in association with decreased fatigue and appetite. This drug, commonly known as "speed," is also used recreationally and as a performance enhancer. According to the United Nations Office on Drugs and Crime (UNODOC) report (2011), more than 10 per cent of adolescents in the U.S. have used amphetamines. In Europe, between two and seven per cent of adolescents have tried amphetamines, and in Canada the number is estimated at just over five per cent.

Study subjects were given one of three dosing regimens of amphetamine during adolescence. When they reached adulthood, drugs were withdrawn and their neurophysiological activity and risk-taking behaviour were studied. "We focused on the key neurotransmitters serotonin, dopamine and norepinephrine," Dr. Gobbi explains. "We found abnormalities in brain activity associated with all three of these neurochemicals, called "monoamines." Imbalances of monoamines are associated with emotional disturbances and mental diseases such as depression or addiction."

Researchers also noted behavioural changes in all dosing groups. Hyperactivity was observed in rodents exposed to a moderate dose of amphetamine during adolescence, while risk-taking behaviour increased in every dosage group.

"Obviously we have to be very cautious about applying these results to a human population," says Dr. Gobbi. "However, given the basic similarities between human and rodent brains, these results are cause for concern. They suggest that the effects of amphetamine use can persist into adulthood, even if the subject is no longer taking drugs, and that these effects include a tendency toward risk-taking behaviour."

This paper was co-authored by Benoit Labontι (Master's student in Dr. Gobbi's lab during the study and currently at the Douglas Mental Health University Institute); Ryan McLaughlin (University of British Columbia, Psychology); Francis Bambico (Yale University, Molecular Psychiatry); Ilaria Lucchino (University La Sapienza, Physiology & Pharmacology); Sergio Dominguez-Lopez, Rafael Ochoa Sanchez, (McGill University, Psychiatry); Marco Leyton, Gabriella Gobbi (McGill University, Psychiatry and RI-MUHC).

Fellowships and scholarships were supported by Fonds de la Recherche en Santι du Quιbec (FRSQ), by the Canadian Institutes of Health Research (CIHR), by the McGill University Health Centre (MUHC) with the Research Institute of the MUHC, and by the Mexican National Council for Science and Technology (CONACYT).


Story Source:

The above story is based on materials provided by McGill University Health Centre. Note: Materials may be edited for content and length.


Journal Reference:

  1. Benoit Labonte, Ryan J. McLaughlin, Sergio Dominguez-Lopez, Francis Rodriguez Bambico, Ilaria Lucchino, Rafael Ochoa-Sanchez, Marco Leyton, Gabriella Gobbi. Adolescent amphetamine exposure elicits dose-specific effects on monoaminergic neurotransmission and behaviour in adulthood. The International Journal of Neuropsychopharmacology, 2011; DOI: 10.1017/S1461145711001544

Cite This Page:

McGill University Health Centre. "Adolescent amphetamine use linked to permanent changes in brain function and behavior." ScienceDaily. ScienceDaily, 3 November 2011. <www.sciencedaily.com/releases/2011/11/111103120446.htm>.
McGill University Health Centre. (2011, November 3). Adolescent amphetamine use linked to permanent changes in brain function and behavior. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/11/111103120446.htm
McGill University Health Centre. "Adolescent amphetamine use linked to permanent changes in brain function and behavior." ScienceDaily. www.sciencedaily.com/releases/2011/11/111103120446.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins